Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetic Gastroparesis Clear all

Conditions: Diabetic Gastroparesis
Interventions: Thoracic Splanchnic Magnetic Neuromodulation Therapy; Device
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Diabetic Gastroparesis
Interventions: Metoclopramide Nasal Spray, Placebo Nasal Spray; Drug
Lead sponsor: Evoke Pharma; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: TAK-906 Maleate, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more

Conditions: Diabetic Gastroparesis
Interventions: CIN-102 Dose 15mg or 10mg, Placebo; Drug
Lead sponsor: CinDome Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 100
States / cities: Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more

Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Interventions: Tradipitant, Placebo, Open Label Tradipitant; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 979 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 36
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 30 more

Conditions: Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
Interventions: Enterra® Therapy System; Device
Lead sponsor: Enterra Medical, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Louisville, Kentucky • Coon Rapids, Minnesota

Conditions: Gastroparesis
Interventions: Observational; Other
Lead sponsor: Stanford University; Other
Eligibility: 20 Years to 49 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Gastroparesis
Interventions: CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3, Placebo; Drug
Lead sponsor: CinDome Pharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Chula Vista, California • Jacksonville, Florida • Miami, Florida + 15 more

Conditions: Diabetics Without Symptoms of Gastroparesis, Diabetic Gastroparesis, Idiopathic Gastroparesis, Total or Partial Gastrectomy, Chronic Nausea, Functional Dyspepsia
Interventions: magnetogastrogram; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 12 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gastroparesis
Interventions: Naronapride, Placebo; Drug
Lead sponsor: Dr. Falk Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 23
States / cities: Chula Vista, California • Lomita, California • Clearwater, Florida + 18 more

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 183
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 144 more

Conditions: Gastroparesis, Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Placebo, 10mg TZP-102, 20mg TZP-102; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Diabetic Gastroparesis
Interventions: senna/docusate; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: NG101, Placebo; Drug
Lead sponsor: Neurogastrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 83
States / cities: Dothan, Alabama • Foley, Alabama • Mobile, Alabama + 69 more

Conditions: Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions: Relamorelin, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 70
States / cities: Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more

Conditions: Gastroparesis
Interventions: velusetrag dose 1, velusetrag dose 2, velusetrag dose 3, placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Tucson, Arizona • Los Angeles, California • Ventura, California + 6 more

Conditions: Diabetic Gastroparesis
Interventions: Reglan ODT; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetes, Gastroparesis With Diabetes Mellitus
Interventions: PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle; Drug · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Crohn Disease, Diabetic Gastroparesis
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Gastroparesis
Interventions: Placebo, Camicinal; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 34
States / cities: Chandler, Arizona • Long Beach, California • Northridge, California + 29 more

Conditions: Gastroparesis
Interventions: GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Concord, California • Indianapolis, Indiana • Chevy Chase, Maryland + 6 more

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 114
States / cities: Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 98 more

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 113
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more

Search by objective public record fields.

Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Study of Enterra Programming with Nocturnal Cycling in Gastroparetics

GI-Challenge Study for Gastroparesis Patients and Healthy Controls

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Biomagnetic Characterization of Gastric Dysrhythmias III

Different Doses of Naronapride vs. Placebo in Gastroparesis

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Gastroparesis Registry 3

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Docusate/Senna for the Treatment of Diabetic Gastroparesis

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis

PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis

Rifaximin in Patients With Diabetic Gastroparesis

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01